The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection.
J Infect Dev Ctries
; 16(1): 101-111, 2022 Jan 31.
Article
in English
| MEDLINE | ID: covidwho-1704553
ABSTRACT
INTRODUCTION:
During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.METHODOLOGY:
We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.RESULTS:
poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.CONCLUSIONS:
The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vascular Endothelial Growth Factor A
/
Poly(ADP-ribose) Polymerase Inhibitors
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Observational study
/
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
J Infect Dev Ctries
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Affiliation country:
Jidc.15386
Similar
MEDLINE
...
LILACS
LIS